Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
149.23
-13.34 (-8.21%)
May 9, 2025, 1:32 PM - Market open
Natera Revenue
Natera had revenue of $501.83M in the quarter ending March 31, 2025, with 36.46% growth. This brings the company's revenue in the last twelve months to $1.83B, up 51.50% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.83B
Revenue Growth
+51.50%
P/S Ratio
11.38
Revenue / Employee
$412,945
Employees
4,434
Market Cap
20.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NTRA News
- 16 hours ago - Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 hours ago - Natera Reports First Quarter 2025 Financial Results - Business Wire
- 1 day ago - Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress - Business Wire
- 2 days ago - Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - Business Wire
- 4 days ago - Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera - Business Wire
- 8 days ago - Natera to Report its First Quarter Results on May 8, 2025 - Business Wire
- 9 days ago - Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction - Business Wire
- 10 days ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha